Lucid-PSYCH

Last updated
Lucid-PSYCH
Clinical data
Other namesLUCID-PSYCH; Lucid-201
Drug class Undefined; Psychedelic; Hallucinogen

Lucid-PSYCH, or LUCID-PSYCH, also known as Lucid-201, is a psychedelic hallucinogen which is under development for the treatment of major depressive disorder. [1] [2] [3] [4] [5] It is under development by Lucid Psycheceuticals. [1] [2] Lucid-PSYCH's exact mechanism of action is undefined. [1] [2] As of March 2023, it is in preclinical research and is progressing to phase 1 clinical trials. [1] [2] [6]

See also

References

  1. 1 2 3 4 "Lucid PSYCH - AdisInsight". adisinsight.springer.com.
  2. 1 2 3 4 "Delving into the Latest Updates on Lucid-201 with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
  3. ↑ "Mental health disorders | Neurodegenerative disorders | Toronto". Archived from the original on 2022-05-31.
  4. ↑ "Our Science". Archived from the original on 2023-06-05.
  5. ↑ https://www.sec.gov/Archives/edgar/data/1771885/000115752321001089/a52478064_ex991.htm "Lucid’s pipeline includes Lucid-201, a psychedelic drug candidate targeting mental health disorders, [...]"
  6. ↑ "Registration". ANZCTR. Retrieved 16 February 2025.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.